PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 2794993-10 1989 The results suggest that the two reversible MAO-A inhibitors Mocl and Brof may lessen the liability to TYR-related hypertensive reactions. Tyramine 103-106 monoamine oxidase A Homo sapiens 44-49 22156310-0 1989 Potentiation of the pressor effect of oral and intravenous tyramine during administration of the selective MAO-A inhibitor moclobemide in healthy volunteers. Tyramine 59-67 monoamine oxidase A Homo sapiens 107-112 2619973-2 1989 Administration of moclobemide--a relatively short-acting, reversible inhibitor of monoamine oxidase-A (MAO-A)--to experimental animals potentiates the pressor responses to intravenously injected tyramine, but such effects are moderate, short-lived, and much less apparent when the tyramine is given orally. Tyramine 195-203 monoamine oxidase A Homo sapiens 103-108 2619973-2 1989 Administration of moclobemide--a relatively short-acting, reversible inhibitor of monoamine oxidase-A (MAO-A)--to experimental animals potentiates the pressor responses to intravenously injected tyramine, but such effects are moderate, short-lived, and much less apparent when the tyramine is given orally. Tyramine 281-289 monoamine oxidase A Homo sapiens 103-108 2587674-9 1989 The results suggest that the two reversible MAO-A inhibitors moclobemide and brofaromine carry a much reduced liability to tyramine-related hypertensive reactions. Tyramine 123-131 monoamine oxidase A Homo sapiens 44-49 3266532-3 1988 Brain selectivity would overcome the risk of tyramine interactions which have been shown to occur with selective MAO-A but not MAO-B inhibitors. Tyramine 45-53 monoamine oxidase A Homo sapiens 113-118 3928010-4 1985 The pressor responses to tyramine were potentiated by the selective MAO-A inhibitor clorgyline (2 mg kg-1) but not by selegiline (1.0 mg kg-1) and AGN 1135 (1.5 mg kg-1), selective MAO-B inhibitors. Tyramine 25-33 monoamine oxidase A Homo sapiens 68-73 3480939-4 1987 Since tyramine releases noradrenaline into the cytoplasm and not by exocytosis, its action is potentiated by inhibition of neuronal MAO-A. Tyramine 6-14 monoamine oxidase A Homo sapiens 132-137 32942081-1 2020 Monoamine oxidases (MAO-A and MAO-B) are mammalian flavoenzyme, which catalyze the oxidative deamination of several neurotransmitters like norepinephrine, dopamine, tyramine, serotonin, and some other amines. Tyramine 165-173 monoamine oxidase A Homo sapiens 20-25 3929314-5 1985 Reductions in plasma 3-methoxy,4-hydroxyphenylglycol (MHPG), used as a possible index of in vivo MAO-A inhibition, were highly correlated with increases in tyramine pressor sensitivity (r = 0.82). Tyramine 156-164 monoamine oxidase A Homo sapiens 97-102 6791210-7 1981 Tyramine pressor sensitivity changes accompanying administration of the MAO inhibitors were highly correlated with decreases in plasma MHPG (r = 0.92), supporting our previous data indicating the rank order of clorgyline greater than pargyline greater than deprenyl for enhancement of tyramine pressor sensitivity and, thus, suggesting that tyramine potentiation is primarily a function of MAO-A rather than MAO-B inhibition. Tyramine 0-8 monoamine oxidase A Homo sapiens 390-395 31647557-0 2020 Kinetic and solvent isotope effects in oxidation of halogen derivatives of tyramine catalyzed by monoamine oxidase A. Tyramine 75-83 monoamine oxidase A Homo sapiens 97-116 30003648-6 2018 Using cardiomyoblasts and primary cardiomyocytes, we demonstrate that chronic MAO-A activation mediated by synthetic (tyramine) and physiological (NE) substrates induces ROS-dependent DNA damage response, activation of cyclin-dependent kinase inhibitors p21cip , p16ink4a , and p15ink4b and typical features of senescence such as cell flattening and SA-beta-gal activity. Tyramine 118-126 monoamine oxidase A Homo sapiens 78-83 31736764-4 2019 Since tyramine is a prototypic substrate of monoamine oxidase A (MAO-A), genetic polymorphisms in MAO-A may also be relevant. Tyramine 6-14 monoamine oxidase A Homo sapiens 44-63 31736764-4 2019 Since tyramine is a prototypic substrate of monoamine oxidase A (MAO-A), genetic polymorphisms in MAO-A may also be relevant. Tyramine 6-14 monoamine oxidase A Homo sapiens 65-70 31736764-4 2019 Since tyramine is a prototypic substrate of monoamine oxidase A (MAO-A), genetic polymorphisms in MAO-A may also be relevant. Tyramine 6-14 monoamine oxidase A Homo sapiens 98-103 31736764-5 2019 The aims of this study were to identify to what extent the interindividual variation in pharmacokinetics and pharmacodynamics of tyramine is determined by genetic polymorphisms in OCT1, CYP2D6, and MAO-A. Tyramine 129-137 monoamine oxidase A Homo sapiens 198-203 31736764-6 2019 Beyond that, we wanted to evaluate tyramine as probe drug for the in vivo activity of MAO-A and OCT1. Tyramine 35-43 monoamine oxidase A Homo sapiens 86-91 30039351-10 2018 Indeed, tyramine antilipolytic effect was impaired by MAO-A inhibition. Tyramine 8-16 monoamine oxidase A Homo sapiens 54-59 28682929-9 2017 In view of the observed, considerable heterogeneity of enzyme activities, we suggest to determine activities of monoamine oxidase A and B to reduce the risk for tyramine-induced hypertension and the serotonergic syndrome during chronic therapy with rasagiline or safinamide. Tyramine 161-169 monoamine oxidase A Homo sapiens 112-131 21628600-2 2012 Pharmacologic inhibition of monoamine oxidase type A (MAO-A), but not MAO-B, poses a risk of the "cheese effect," a hypertensive response to excess dietary tyramine, a biogenic sympathomimetic amine. Tyramine 156-164 monoamine oxidase A Homo sapiens 28-52 21628600-2 2012 Pharmacologic inhibition of monoamine oxidase type A (MAO-A), but not MAO-B, poses a risk of the "cheese effect," a hypertensive response to excess dietary tyramine, a biogenic sympathomimetic amine. Tyramine 156-164 monoamine oxidase A Homo sapiens 54-59 17561096-4 2007 Silencing MAO-A by siRNA, pharmacological MAO-A inhibitors (pargyline and Ro41-1049), and the antioxidant/ROS scavenger butylated hydroxytoluene (BHT) inhibited the signaling cascade, suggesting that ROS generated during tyramine oxidation by MAO-A are required. Tyramine 221-229 monoamine oxidase A Homo sapiens 10-15 21224199-5 2011 If MAO-A inhibition occurs, the body cannot protect itself from exogenous amines such as tyramine. Tyramine 89-97 monoamine oxidase A Homo sapiens 3-8 17561096-1 2007 The degradation of biogenic amines by monoamine oxidase A (MAO-A) generates reactive oxygen species (ROS) which participate in serotonin and tyramine signaling. Tyramine 141-149 monoamine oxidase A Homo sapiens 38-57 17561096-1 2007 The degradation of biogenic amines by monoamine oxidase A (MAO-A) generates reactive oxygen species (ROS) which participate in serotonin and tyramine signaling. Tyramine 141-149 monoamine oxidase A Homo sapiens 59-64 22078410-9 2011 As reversible inhibitors of MAO-A, tetrahydropyridine analogs are at low risk of having an adverse effect of tyramine-induced hypertension. Tyramine 109-117 monoamine oxidase A Homo sapiens 28-33 17868200-3 2007 An exception is the extensive investigation carried out on the inhibition of the metabolism of tyramine, when tyramine-containing food is ingested by subjects taking inhibitors of MAO A or of both MAO A and B. Tyramine 95-103 monoamine oxidase A Homo sapiens 180-185 17868200-3 2007 An exception is the extensive investigation carried out on the inhibition of the metabolism of tyramine, when tyramine-containing food is ingested by subjects taking inhibitors of MAO A or of both MAO A and B. Tyramine 95-103 monoamine oxidase A Homo sapiens 197-202 17868200-3 2007 An exception is the extensive investigation carried out on the inhibition of the metabolism of tyramine, when tyramine-containing food is ingested by subjects taking inhibitors of MAO A or of both MAO A and B. Tyramine 110-118 monoamine oxidase A Homo sapiens 180-185 17868200-3 2007 An exception is the extensive investigation carried out on the inhibition of the metabolism of tyramine, when tyramine-containing food is ingested by subjects taking inhibitors of MAO A or of both MAO A and B. Tyramine 110-118 monoamine oxidase A Homo sapiens 197-202 17561096-7 2007 These findings demonstrate that H(2)O(2)-generated during tyramine oxidation by MAO-A triggers a stress-induced mitogenic signaling via the MMP2/sphingolipid pathway, which could participate in excessive remodeling and alteration of the vascular wall. Tyramine 58-66 monoamine oxidase A Homo sapiens 80-85 17284087-2 2007 However, MAO-A is also inhibited at the high oral dosages needed to effectively treat depression (not an approved indication), necessitating a tyramine-restricted diet. Tyramine 143-151 monoamine oxidase A Homo sapiens 9-14 17401530-2 2007 With the exception of the inhibition of the metabolism of tyramine ingested by subjects taking inhibitors of MAO-A or of both MAO-A and -B, which has been extensively investigated, the involvement of the monoamine oxidases in xenobiotic amine metabolism (drugs in particular) has been largely neglected. Tyramine 58-66 monoamine oxidase A Homo sapiens 109-114 17401530-2 2007 With the exception of the inhibition of the metabolism of tyramine ingested by subjects taking inhibitors of MAO-A or of both MAO-A and -B, which has been extensively investigated, the involvement of the monoamine oxidases in xenobiotic amine metabolism (drugs in particular) has been largely neglected. Tyramine 58-66 monoamine oxidase A Homo sapiens 126-138 9622553-3 1998 It is believed that a monoamine oxidase (MAO) inhibitor specific for MAO A, which is reversibly bound to this enzyme and displaceable by tyramine, will be an antidepressant which will not cause a rise in blood pressure when tyramine-containing foods are ingested. Tyramine 137-145 monoamine oxidase A Homo sapiens 69-74 10647887-7 1999 The uVNTR genotype may be a common genetic determinant of significant individual differences in oxidizing capacity for critical MAO-A substrates, which include serotonin, norepinephrine, and tyramine. Tyramine 191-199 monoamine oxidase A Homo sapiens 128-133 10498294-5 1999 Our results showed that cell incubation with tyramine (50 micromol/l) led to a time-dependent H2O2 generation which was fully inhibited by MAO A (clorgyline and RO 41-1049) and MAO B (selegiline and RO 19-6327) inhibitors. Tyramine 45-53 monoamine oxidase A Homo sapiens 139-144 12855685-1 2003 Monoamine oxidase (MAO) A and B catalyze the oxidative deamination of neuroactive and dietary monoamines such as serotonin, tyramine, and phenylethylamine. Tyramine 124-132 monoamine oxidase A Homo sapiens 0-25 12765230-6 2003 Although dietary restrictions during moclobemide therapy are not considered necessary, the combination of large quantities of moclobemide and tyramine-containing products seems to be lethal, probably because monoamine oxidase-A selectivity is overwhelmed after massive overdoses. Tyramine 142-150 monoamine oxidase A Homo sapiens 208-227 10571247-4 1999 Characterization of the enzyme isoforms by inhibition profiles of [14C]tyramine oxidation and Western and Northern blot analyses showed that mRNAs and proteins related to both monoamine oxidases A and B were expressed in adipocytes. Tyramine 71-79 monoamine oxidase A Homo sapiens 176-202 9663810-22 1998 CONCLUSIONS: The potentiation of tyramine-evoked mydriasis by moclobemide is likely to reflect the inhibition of MAO-A activity in the iris, consistent with the activity of this enzyme in sympathetic nerve terminals. Tyramine 33-41 monoamine oxidase A Homo sapiens 113-118 9622553-3 1998 It is believed that a monoamine oxidase (MAO) inhibitor specific for MAO A, which is reversibly bound to this enzyme and displaceable by tyramine, will be an antidepressant which will not cause a rise in blood pressure when tyramine-containing foods are ingested. Tyramine 224-232 monoamine oxidase A Homo sapiens 69-74 8695909-6 1996 The maoA gene forms an operon with the maoC gene, which has similarity to a dehydrogenase involved in the tyramine metabolism. Tyramine 106-114 monoamine oxidase A Homo sapiens 4-8 9503566-2 1997 Although tyramine is a substrate for both MAO-A and -B, it is only inhibitors of the former enzyme, which are also the effective antidepressants, that give rise to the cheese reaction. Tyramine 9-17 monoamine oxidase A Homo sapiens 42-54 9503566-5 1997 The development of reversible inhibitors of monoamine oxidase-A (RIMAs) has reduced this hypertensive response since rising tyramine concentrations can displace the inhibitor from the enzyme and thus allow some metabolism to occur. Tyramine 124-132 monoamine oxidase A Homo sapiens 44-63 8695909-1 1996 Bacterial cells respond to monoamine compounds, such as tyramine, dopamine, octopamine, or norepinephrine, and induce the syntheses of tyramine oxidase encoded by tynA and monoamine oxidase encoded by maoA. Tyramine 56-64 monoamine oxidase A Homo sapiens 201-205 1609337-6 1992 The reversible inhibitors of monoamine oxidase A (RIMAs) are a group of drugs that, by producing inhibition selectively of monoamine oxidase A (MOA-A), still allow metabolism of tyramine by MAO-B. Tyramine 178-186 monoamine oxidase A Homo sapiens 29-48 8390270-1 1993 The "cheese effect", potentiation of sympathomimetic action of indirectly acting amines such as tyramine, the main side effect of irreversible non-selective and selective monoamine oxidase (MAO) A inhibitors, has largely been eliminated in the new generation of reversible selective MAO-A and B and irreversible MAO-B inhibitors. Tyramine 96-104 monoamine oxidase A Homo sapiens 171-196 8390270-1 1993 The "cheese effect", potentiation of sympathomimetic action of indirectly acting amines such as tyramine, the main side effect of irreversible non-selective and selective monoamine oxidase (MAO) A inhibitors, has largely been eliminated in the new generation of reversible selective MAO-A and B and irreversible MAO-B inhibitors. Tyramine 96-104 monoamine oxidase A Homo sapiens 283-288 8861736-1 1996 The objective of this study was to assess the tyramine pressor sensitivity during combined administration of selective and reversible inhibitors of monoamine oxidase A and B, viz. Tyramine 46-54 monoamine oxidase A Homo sapiens 148-173 8861736-14 1996 The low amount of oral tyramine needed (51 + or - 20 mg) to induce relevant increases in blood pressure indicates that dietary precautions are needed when both MAO-A and B are inhibited by 2 reversible inhibitors. Tyramine 23-31 monoamine oxidase A Homo sapiens 160-171 8313394-3 1993 However, BW 1370U87 differs from most other MAO inhibitors in that its mechanism of action follows simple competitive kinetics, so that an unusually high concentration of tyramine in peripheral tissues may displace the inhibitor from MAO-A sites in the intestine and liver. Tyramine 171-179 monoamine oxidase A Homo sapiens 234-239 8313396-4 1993 The introduction of reversible inhibitors of monoamine oxidase-A (RIMAs) has greatly reduced both the number and severity of these interactions and, in particular, the risk of hypertensive crises following the ingestion of tyramine (the "cheese effect"). Tyramine 223-231 monoamine oxidase A Homo sapiens 45-64 1609337-6 1992 The reversible inhibitors of monoamine oxidase A (RIMAs) are a group of drugs that, by producing inhibition selectively of monoamine oxidase A (MOA-A), still allow metabolism of tyramine by MAO-B. Tyramine 178-186 monoamine oxidase A Homo sapiens 123-142 1546143-4 1992 Potentiation of the cardiovascular effects of tyramine is less pronounced after taking moclobemide than after irreversible MAO-A inhibitors. Tyramine 46-54 monoamine oxidase A Homo sapiens 123-128 1483487-1 1992 An open study was carried out to examine the effect of moclobemide, a new antidepressant reversible inhibitor of MAO-A, on the pressor response induced by oral tyramine added to meals of different lipid and protein composition, and to correlate the blood pressure increase in the tyramine test with that obtained during an exercise test. Tyramine 160-168 monoamine oxidase A Homo sapiens 113-118 1609114-6 1992 In the intestinal tract tyramine is mainly metabolized by MAO-A. Tyramine 24-32 monoamine oxidase A Homo sapiens 58-63 2248084-6 1990 Potentiation of the tyramine pressor effect is mainly influenced by the irreversibility and degree of MAO-A inhibition. Tyramine 20-28 monoamine oxidase A Homo sapiens 102-107 1741773-8 1991 The ratio, MAO A molecular activity:MAO B molecular activity decreased in the order: serotonin (35:1) greater than tryptamine (12:1) greater than tyramine (3.3:1) greater than dopamine (2.4:1) greater than benzylamine (1:23). Tyramine 146-154 monoamine oxidase A Homo sapiens 11-16 1759390-7 1991 In deprenyl pretreated mitochondria the potency of MAO-A-dependent effects of these amines was: serotonin greater than tyramine much greater than much greater than 2-phenylethylamine. Tyramine 119-127 monoamine oxidase A Homo sapiens 51-56 2248084-7 1990 Tyramine sensitivity was raised (a factor of 10-30) by all irreversible MAO inhibitors in doses inhibiting MAO-A; it diminished with increasing reversibility. Tyramine 0-8 monoamine oxidase A Homo sapiens 107-112